-
Mashup Score: 1
Complete response rate strongly correlated with lower SLiM-CRAB incidence and biochemical progression in those with high-risk smoldering multiple myeloma.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 2
Panelists discuss how to optimize treatment selection and sequencing for a 65-year-old patient with standard-risk, transplant-eligible newly diagnosed multiple myeloma (NDMM) through assessment of disease characteristics, patient factors, and available therapeutic options.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
Panelists discuss how to optimize treatment selection and sequencing for a 65-year-old patient with standard-risk, transplant-eligible newly diagnosed multiple myeloma. #mmsm | @MoffittNews @bhemato @Rfonsi1 https://t.co/L2ZO48Ey1f
-
-
Mashup Score: 0
Having extramedullary disease correlated with worse PFS and OS among patients who received belantamab mafodotin for relapsed/refractory multiple myeloma.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
The median progression-free survival was 5 months (95% CI, 1-20), and the median OS was 12 months (95% CI, 3-28). #mmsm https://t.co/l6WaDoUP5K
-
-
Mashup Score: 7
The panelist discusses how the KarMMa-3 trial data demonstrated the superior efficacy of ide-cel vs standard regimens in triple-class exposed R/R MM, with a median progression-free survival of 13.3 vs 4.4 months and an overall response rate of 71% vs 42%. The favorable safety profile and significant survival benefit support ide-cel as a preferred option for third-line and greater treatment, particularly in patients with good performance status who can tolerate bridging therapy.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
The panelist discusses how the KarMMa-3 trial data demonstrated the superior efficacy of ide-cel vs standard regimens in triple-class exposed RRMM, with a median PFS of 13.3 vs 4.4 months and an ORR of 71% vs 42%. #mmsm | @cityofhope https://t.co/ADuh03BRzZ
-
-
Mashup Score: 0Expert Insights: Evolving Treatment Landscape in NDMM - 6 day(s) ago
Panelists discuss how the treatment paradigm for newly diagnosed multiple myeloma (NDMM) has evolved from conventional chemotherapy to modern regimens incorporating novel agents like proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies while highlighting persistent challenges including optimizing treatment sequencing and addressing high-risk disease.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
Panelists discuss how the treatment paradigm for newly diagnosed multiple myeloma has evolved from conventional chemotherapy to modern regimens incorporating novel agents. #mmsm https://t.co/v3hQYLFm41
-
-
Mashup Score: 2
Panelists discuss the data surrounding the use of CAR-T therapy in earlier lines of treatment for relapsed/refractory multiple myeloma (R/R MM), including findings from the cilta-cel (Popat R, et al. ASH 2024 No. 1032; Mateos MV, et al. IMS 2024 No. OA-65), and Idel-cel (Ailawadhi S, et al. Blood 2024) studies, and share their thoughts on the implications of these results.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
Panelists discuss the data surrounding the use of CAR-T therapy in earlier lines of treatment for relapsed/refractory multiple myeloma. #mmsm | @SagarLonialMD @AjayNookaMD @nishjo76 @JKaufmanMD https://t.co/HBD7nhm4VP
-
-
Mashup Score: 4
The panelist discusses how the treatment landscape for early-stage relapsed/refractory multiple myeloma (R/R MM) has evolved significantly with CAR T-cell therapies (idecabtagene vicleucel, ciltacabtagene autoleucel [ide-cel, cilta-cel]) and novel drug combinations. Treatment selection now considers prior therapies, patient characteristics, and response duration. For third-line chimeric antigen receptor (CAR) T after no prior CAR T use, cilta-cel shows favorable efficacy data with deeper, more durable responses than ide-cel, though both are viable options.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
WATCH: Evolving Paradigms, CAR T, and Treatment Selection in Early-Stage R/R MM | #mmsm @cityofhope https://t.co/7dZUlI578T
-
-
Mashup Score: 16Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone Induction in Newly Diagnosed Myeloma: Analysis of the MIDAS Trial - 8 day(s) ago
Key Points. Induction therapy with IsaKRD in the MIDAS study yielded the highest pre-transplant MRD-negativity rates ever reported in TE NDMM patientsThe f
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
#mmsm @BloodJournal MIDAS study of IsaKRD-results of induction /6 cycles n=791 8% high risk cytogenetics 91% VGPR or better MRD negativity: ~ 2/3 achieved to 10-5 and 1/2 achieved 10-6 ➡️ https://t.co/mrPmR6Ked7 Imp study with post-induction MRD assessment for guiding… https://t.co/TzkuzAdRsG https://t.co/W85YwIcNf9
-
-
Mashup Score: 3
Ashraf Z. Badros, MB, ChB, discusses the background, methods, and design of the phase 3 AURIGA trial.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
Ashraf Z. Badros, MB, ChB, discusses the background, methods, and design of the phase 3 AURIGA trial. #mmsm @UMGCCC https://t.co/MzsfSHd8N8
-
-
Mashup Score: 2
Patients with relapsed or refractory multiple myeloma should consider quality of life with survival when choosing the most suitable treatment option.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet-
Before deciding on a treatment regimen for relapsed or refractory multiple myeloma, it's important for patients to talk to their doctors about any quality of life considerations, according to Dr. Henry Fung of @FoxChaseCancer. #MMSM Read more: https://t.co/00u4OkhOus
-
Efficacy results from the trial reveal that at a median follow-up of 50 months (range, 8-61) the primary end point of progression-free survival was not reached (NR; 95% CI, 57.7-NR). #mmsm | @OmarNadeemMD https://t.co/vdbJmf3sOP